Clinical and biochemical characteristics of the 129 cirrhotic patients subdivided according to one year survival
| Surviving patients | Deceased patients | p Value | |
|---|---|---|---|
| Data are median (range). | |||
| INR, international normalised ratio; MELD, model for end stage liver disease; MELDaetiology, model for end stage liver disease computed including aetiology of liver disease; MEGX, monoethylglycinexylidide. | |||
| Sex (M/F) | 70/28 | 25/6 | NS |
| Age (y) | 48 (22–75) | 51 (31–71) | NS |
| Encephalopathy (yes/no) | 7/91 | 5/26 | NS |
| Ascites (yes/no) | 32/66 | 21/10 | 0.0007 |
| Bilirubin (mg/dl) | 2 (0.3–12) | 2.4 (0.4–7) | NS |
| Albumin (g/dl) | 3.5 (2.4–5) | 3.4 (2.3–5) | NS |
| Prothrombin activity (%) | 59 (31–100) | 52 (30–85) | 0.01 |
| Child-Pugh score | 7 (5–12) | 9 (5–14) | 0.001 |
| Creatinine (mg/dl) | 0.9 (0.6–1.3) | 1.0 (0.7–1.2) | NS |
| INR | 1.6 (1.0–2.9) | 1.8 (1.1–2.9) | 0.01 |
| MELD score | 6 (−5–17) | 9 (0–19) | 0.003 |
| MELDaetiology score | 12 (−5–23) | 15 (0–25) | 0.003 |
| MEGX15 (ng/ml) | 16 (0–110) | 8 (0–44) | 0.003 |
| MEGX30 (ng/ml) | 21 (2–91) | 10 (1–63) | <0.001 |
| MEGX60 (ng/ml) | 27 (4–93) | 18 (1–46) | <0.01 |